Publications by authors named "Tariq Aziz Khan"
Background: In preliminary findings from the recurrent or metastatic cervical cancer cohort of CheckMate 358, nivolumab showed durable anti-tumour responses, and the combination of nivolumab plus ipilimumab showed promising clinical activity. Here, we report long-term outcomes from this cohort.
Methods: CheckMate 358 was a phase 1-2, open-label, multicohort trial.
Article Synopsis
- The John Cunningham Virus (JCV) causes progressive multifocal leukoencephalopathy, leading to severe neurological symptoms with no current effective treatment.
- Researchers used immunoinformatics to identify immunogenic and non-allergenic epitopes from JCV proteins, aiming to create a subunit vaccine.
- The study demonstrated that the designed vaccines are stable, can elicit a strong immune response, and may provide a promising approach for preventing JCV infections.
Importance: There remains an unmet need to improve clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Objective: To evaluate clinical benefit of first-line nivolumab plus ipilimumab vs nivolumab alone in patients with R/M SCCHN.
Design, Setting, And Participants: The CheckMate 714, double-blind, phase 2 randomized clinical trial was conducted at 83 sites in 21 countries between October 20, 2016, and January 23, 2019.
Purpose: CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus fluorouracil ≤ six cycles, then cetuximab maintenance) in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Methods: Patients without prior systemic therapy for R/M SCCHN were randomly assigned 1:1 to nivolumab plus ipilimumab or EXTREME.